2[1]Allannic H, Fauchet R, Orgiazzi J, Orgi azzi J, Madec AM, Genetet B, Lorcy Y, Le Guerrier AM, Delambre C, Derennes V. An tithyroid drugs and Graves' disease: A prospective randomized evaluation of the efficacy of trea tment duration [J]. J Clin Endocrinol Metab, 1990；70(3):675-679.
3[2]Misaki T, Konishi J, Iida Y, Endo K, To rizuka K. Altered balance of immunoregulator y T Lymphocyte subsets in autoimmune thyroid disease [J]. Acta Endoc, 1984 ；105(2):200-204.
4[3]Ishikawa N, Equchi K, Otsubo T, Ueki Y, Fukuda T, Tezuka H, Matsunaga M, Kawabe Y, Shimomura C, Izumi M. Reduction i n the suppressor-ind ucer T cell subset and increase in the helper T cell sebset in thyroid tissue fr om patients with Graves' disease [J]. J Clin Endocrinol Metab, 1987；65( 1):17-18.
1[3]Beckmann C, Kurts I, Klebba B. The role of CD30 in skin and heart allograft refection in the mouse [J]. Transplant Proc,2001;33(8):140-141.
2[4]Pelzl S, Opelz G, Daniel V. Evaluation of posttransplantation soluble CD30 for diagaosis of acute renal allograft refection[J]. Transplantation, 2003;15(6):421-423.
